Abstract

Info

Title:: Preparation?f PEDF-loaded polymer ultrasound microbubbles and its properties

Author(s):: HU Jie1; 2; JIAO Mingke3; LIU Lijie3; ZHANG Peng3; NIU Yingying3; 1. Department of Echocardiography, the Fourth Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China 2. Department of Ultrasound, Yubei District Peoples Hospital of Chongqing, Chongqing 400000, China 3. Department of Biomedical Engineering, General Hospital of Xinjiang Military Region, Urumqi 830000, China

Keywords:: Keywords: angiogenic disease pigm entepithelium-derived factor ultrasound microbubble targeted treatment

Abstract:: Abstract: Objective To develop the polymer ultrasound microbubbles with the maximum binding rate to pigm entepithelium-derived factor (PEDF) for angiogenic diseases, and to clarify the physical and chemical properties. Methods Polymer ultrasound microbubbles were prepared by acoustic cavitation method. After PEDF was divided into different groups (0.4, 2.0, 10.0 and 50.0 μg/mL) according to the concentration, it was encapsulated with liposomes using transmembrane gradient method, which enabled PEDF to bind to ultrasound microbubbles, and then the binding was observed under fluorescence microscope. The maximum binding rate of PEDF to ultrasound microbubbles was obtained by flow cytometry. Moreover, the efficiency of encapsulating PEDF into liposomes and the in vitro drug release characteristics of the drug-loaded ultrasound microbubbles were determined by fluorescence spectrophotometry. Results The polymer ultrasound microbubbles which had a maximum binding rate of (96.14±1.21)% to PEDF was successfully prepared. The efficiency of encapsulating PEDF into liposomes was about (79.20±2.31)%. The in vitro drug release concentration reached the maximum in 1 min after the microbubble breaking, and the concentration was obviously reduced after the continuous release for 10 min. Conclusion The polymer ultrasound microbubbles with a high binding rate to PEDF can be used as a suitable drug loader for targeted treatment of angiogenic diseases.